v3.25.3
Consolidated Balance Sheets - USD ($)
Jul. 31, 2025
Jul. 31, 2024
CURRENT ASSETS:    
Cash and cash equivalents $ 10,493,808 $ 862,089
Short-term investments 7,372,473
Amounts receivable and prepaid expenses 2,060,295 2,791,765
Total current assets 19,926,576 3,653,854
NON-CURRENT ASSETS:    
Equity investment in BC Therapeutics 524,278 418,490
Intangible assets, net 184,525 199,796
Property and equipment, net 296,819 388,175
Long term prepaid expenses 717,508 1,211,946
Total non-current assets 1,723,130 2,218,407
Total assets 21,649,706 5,872,261
CURRENT LIABILITIES:    
Trade payables 3,283,703 7,170,781
Accrued expenses and other payables 694,285 290,376
Total current liabilities 3,977,988 7,461,157
NON-CURRENT LIABILITIES:    
Warrant liability 337,672 1,096,036
Total non-current liabilities 337,672 1,096,036
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY (DEFICIT):    
Share Capital of no par value – Authorized: unlimited at July 31, 2025 and 2024; Issued and outstanding: 1,883,906 and 121,907 shares at July 31, 2025 and 2024, respectively 101,739,923 72,166,414
Share-based payment reserved 10,316,140 9,189,261
Warrant reserve 17,719,026 1,844,296
Accumulated other comprehensive loss (138,684) (138,684)
Non-controlling interest (546,795) (302,522)
Accumulated deficit (111,755,564) (85,443,697)
Total shareholders’ equity (deficit) 17,334,046 (2,684,932)
Total liabilities and shareholders’ equity (deficit) $ 21,649,706 $ 5,872,261